We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.55%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$899M
AUM Growth
+$163M
Cap. Flow
+$26.4M
Cap. Flow %
2.93%
Top 10 Hldgs %
55.22%
Holding
69
New
9
Increased
12
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$23M
2
IBB icon
iShares Biotechnology ETF
IBB
+$16.5M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.1M
4
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$6.7M
5
AGN
Allergan Inc
AGN
+$6.6M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$16.4M
2
PBYI icon
Puma Biotechnology
PBYI
+$13.6M
3
IMGN
Immunogen Inc
IMGN
+$6.53M
4
MDVN
MEDIVATION, INC.
MDVN
+$6.52M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 84.05%
2 Financials 1.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
51
Madrigal Pharmaceuticals
MDGL
$11.4B
$3.09M 0.34%
13,993
+3,229
+30% +$687K
CVS icon
52
CVS Health
CVS
$134B
$3.05M 0.34%
53,694
-17,897
-25% -$1.07M
LITS
53
Lite Strategy Inc
LITS
$33.6M
$2.77M 0.31%
12,196
+4,755
+64% +$743K
NPSP
54
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$1.94M 0.22%
+60,860
New +$1.4M
GENT
55
DELISTED
GENTIUM SPA ADS
GENT
$1.75M 0.19%
+64,543
New +$1.05M
RPTP
56
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$1.64M 0.18%
+110,000
New +$1.32M
ALNY icon
57
Alnylam Pharmaceuticals
ALNY
$27.4B
$1.52M 0.17%
+23,745
New +$1.18M
CLVS
58
DELISTED
Clovis Oncology, Inc.
CLVS
$1.38M 0.15%
+22,687
New +$1.61M
ACHV icon
59
Achieve Life Sciences
ACHV
$647M
$1.05M 0.12%
51
– –
SUPN icon
60
Supernus Pharmaceuticals
SUPN
$2.65B
$1.03M 0.11%
140,800
– –
AEGR
61
DELISTED
Aegerion Pharmaceuticals
AEGR
$1.02M 0.11%
+11,880
New +$1.01M
ICAD
62
DELISTED
iCAD Inc
ICAD
$467K 0.05%
88,527
– –
CERE
63
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$426K 0.05%
35,748
-16,312
-31% -$224K
RIGL icon
64
Rigel Pharmaceuticals
RIGL
$704M
– –
-82,710
Closed -$2.76M
IMGN
65
DELISTED
Immunogen Inc
IMGN
– –
-393,773
Closed -$6.53M
ECYT
66
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-60,200
Closed -$790K
DNDN
67
DELISTED
DENDREON CORPORATION
DNDN
– –
-376,728
Closed -$1.55M
CRTX
68
DELISTED
CORNERSTONE THERAPEUTICS INC
CRTX
– –
-66,112
Closed -$529K
GCVRZ
69
DELISTED
Sanofi Contingent Value Rights
GCVRZ
– –
-103,665
Closed -$200K
1 2
3

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, Tekla Capital Management held 69 positions worth $899M, up 22% from $735M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Tekla Capital Management's Q3 2013 filing shows 9 new, 12 increased, 10 reduced and 6 closed positions. Its largest new stake was iShares Biotechnology ETF: 251,820 shares worth $17.6M. The largest sale was ONYX PHARMACEUTICALS INC, an estimated $16.4M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 84% a quarter earlier, followed by Financials.

  • Tekla Capital Management's largest Q3 2013 buy was iShares Biotechnology ETF: 251,820 shares worth $17.6M.
  • Tekla Capital Management added most to Amgen in Q3 2013, an estimated $23M increase.
  • Tekla Capital Management's biggest Q3 2013 reduction was ONYX PHARMACEUTICALS INC, cutting an estimated $16.4M.
  • Tekla Capital Management fully exited Immunogen Inc in Q3 2013, selling an estimated $6.53M.
  • Tekla Capital Management's ten largest holdings make up 55% of its $899M portfolio in Q3 2013.
  • Tekla Capital Management opened 9 new positions and closed 6 in Q3 2013.
  • Tekla Capital Management's portfolio value rose 22% quarter-over-quarter to $899M.

Based on Tekla Capital Management's 13F filing for Q3 2013, filed 30 Oct 2013.